97 related articles for article (PubMed ID: 26084931)
1. Amiloride: the "new" renal tonic?
Warnock DG
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F429-30. PubMed ID: 26084931
[No Abstract] [Full Text] [Related]
2. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Hinrichs GR; Weyer K; Friis UG; Svenningsen P; Lund IK; Nielsen R; Mollet G; Antignac C; Bistrup C; Jensen BL; Birn H
Acta Physiol (Oxf); 2019 Dec; 227(4):e13362. PubMed ID: 31423748
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
[TBL] [Abstract][Full Text] [Related]
5. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
Andersen H; Hansen PB; Bistrup C; Nielsen F; Henriksen JE; Jensen BL
J Hypertens; 2016 Aug; 34(8):1621-9. PubMed ID: 27214087
[TBL] [Abstract][Full Text] [Related]
6. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Oxlund CS; Buhl KB; Jacobsen IA; Hansen MR; Gram J; Henriksen JE; Schousboe K; Tarnow L; Jensen BL
J Am Soc Hypertens; 2014 Dec; 8(12):872-81. PubMed ID: 25492830
[TBL] [Abstract][Full Text] [Related]
7. [New insights into the pathophysiology of oedema in nephrotic syndrome].
Rondon-Berrios H
Nefrologia; 2011; 31(2):148-54. PubMed ID: 21461007
[TBL] [Abstract][Full Text] [Related]
8. Sodium retention by uPA in nephrotic syndrome?
Ehmke H
Acta Physiol (Oxf); 2020 Jan; 228(1):e13393. PubMed ID: 31559686
[No Abstract] [Full Text] [Related]
9. Fast Nongenomic Effect of Aldosterone on the Volume of Principal Cells in Collecting Tube and Genetic Heterogeneity of Epithelial Sodium Channel in the Postnatal Ontogenesis of Rat Kidney.
Logvinenko NS; Gerbek YE; Solenov EI; Ivanova LN
Bull Exp Biol Med; 2016 Mar; 160(5):691-4. PubMed ID: 27021081
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
11. Tubuloglomerular and connecting tubuloglomerular feedback during inhibition of various Na transporters in the nephron.
Wang H; D'Ambrosio MA; Ren Y; Monu SR; Leung P; Kutskill K; Garvin JL; Janic B; Peterson EL; Carretero OA
Am J Physiol Renal Physiol; 2015 May; 308(9):F1026-31. PubMed ID: 25715987
[TBL] [Abstract][Full Text] [Related]
12. Blockade of ENaCs by amiloride induces c-Fos activation of the area postrema.
Miller RL; Denny GO; Knuepfer MM; Kleyman TR; Jackson EK; Salkoff LB; Loewy AD
Brain Res; 2015 Mar; 1601():40-51. PubMed ID: 25557402
[TBL] [Abstract][Full Text] [Related]
13. Evans Blue is not a suitable inhibitor of the epithelial sodium channel δ-subunit.
Perniss A; Wolf A; Wichmann L; Schönberger M; Althaus M
Biochem Biophys Res Commun; 2015 Oct; 466(3):468-74. PubMed ID: 26365349
[TBL] [Abstract][Full Text] [Related]
14. Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells.
Wilson HM; Reid FJ; Brown PA; Power DA; Haites NE; Booth NA
Exp Nephrol; 1993; 1(6):343-50. PubMed ID: 8081986
[TBL] [Abstract][Full Text] [Related]
15. NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia.
Coote KJ; Paisley D; Czarnecki S; Tweed M; Watson H; Young A; Sugar R; Vyas M; Smith NJ; Baettig U; Groot-Kormelink PJ; Gosling M; Lock R; Ethell B; Williams G; Schumacher A; Harris J; Abraham WM; Sabater J; Poll CT; Faller T; Collingwood SP; Danahay H
Br J Pharmacol; 2015 Jun; 172(11):2814-26. PubMed ID: 25573195
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the plasminogen system on rat glomerular epithelial cells.
Kanalas JJ
Exp Cell Res; 1995 Jun; 218(2):561-6. PubMed ID: 7796890
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
18. Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors.
Dyer KD; Linz-Mcgillem LA; Alliegro MA; Alliegro MC
Cell Biol Int; 2002; 26(4):327-35. PubMed ID: 11991662
[TBL] [Abstract][Full Text] [Related]
19. Ethyl isopropyl amiloride inhibits smooth muscle cell proliferation and migration by inducing apoptosis and antagonizing urokinase plasminogen activator activity.
Chen YX; O'Brien ER
Can J Physiol Pharmacol; 2003 Jul; 81(7):730-9. PubMed ID: 12897821
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of sodium retention in nephrotic syndrome: role of aldosterone and glomerular filtration].
Reubi FC; Weidmann P
J Urol Nephrol (Paris); 1978 Sep; 84(9):643-6. PubMed ID: 748584
[No Abstract] [Full Text] [Related]
[Next] [New Search]
